Important Biotech Catalysts For September 12, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ:MRSN) lead candidate…
Adamis Achieves Enrolment Target In Mid-Stage Covid-19 Study, Awaits Data Safety Monitoring Board Review Later This Month
Adamis Pharmaceuticals (NASDAQ: ADMP) announced that it has reached the initial planned enrollment target in the ongoing U.S. Phase 2/3 clinical trial investigating Tempol as a treatment for COVID-19.
Agenus Begins Mid-Stage Global Studies On Colorectal And Skin Cancer Candidate
Agenus (NASDAQ: AGEN) has initiated Phase 2 ACTIVATE trials of botensilimab to advance globally in metastatic patients who have progressed on available therapies.
This global Phase 2 program include clinical trials of ACTIVATE-Colorectal and ACTIVATE-Melanoma studies.
BioLineRx Seeks FDA Nod For Stem Cell Mobilization Candidate
BioLineRx (NASDAQ: BLRX) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate Motixafortide in stem cell mobilization (SCM) for autologous bone marrow transplantation for multiple myeloma patients.
Analyst Outlines Doubts On This NASH-Focused Stock, Builds Neutral Case
HC Wainwright initiated Terns Pharmaceutical Inc (NASDAQ:TERN) with a Neutral rating and a price target of $6.00. The biopharmaceutical company has a…
This Cancer Focused Stock Has 60% Potential Upside, Bullish Analyst Says
HC Wainwright initiated coverage on Rain Therapeutics Inc (NASDAQ:RAIN), with a price target of $10 with a Buy rating. With an upside…
Deciphera Earns Price Target Bump With Encouraging ESMO Presentation
Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) announced positive initial data from the single agent dose escalation portion of the Phase 1 study of…
IDEAYA Shares Jump On Positive Interim Data From Eye Cancer Trial
The shares of oncology-focused Ideaya Biosciences Inc (NASDAQ: IDYA) are trading higher after interim data from its solid tumor candidate darovasertib with cancer…
BioMarin Says One Participant Diagnosed With Leukemia In Late-Stage Hemophilia Gene Therapy Trial
In an SEC filing, BioMarin Pharmaceutical Inc (NASDAQ:BMRN) said that, in August, a participant in its valoctocogene roxaparvovec (BMN 270)…
POINT Biopharma Shares Jump After Updated Efficacy, Safety Data From Prostate Cancer Candidate
POINT Biopharma Global Inc (NASDAQ:PNT) shared updated efficacy and safety data from the 27-patient lead-in cohort for the Company’s phase 3…